The Indian drug regulator has granted emergency use authorization for Biological E’s COVID-19 vaccine Corbevax for children aged five to twelve years, ZycovD (Zydus Cadila vaccine) for children aged twelve and up, and Bharat Biotech’s Covaxin for children aged six to twelve years. The approval by the Drugs Controller General of India (DCGI) follows recommendations by the Central Drugs Standard Control Organization’s Subject Expert Committee (SEC) on COVID-19 (CDSCO). The SEC reviewed the applications of the companies seeking emergency use authorization for use in children last week.
Union Minister of Health and Family Welfare Mansukh Mandaviya on Tuesday announced that India’s fight against Covid-19 has become stronger with emergency use permission to Covaxin, Corbevax and ZyCoV-D.
Corbevax from Biological E is being used to immunise children aged 12 to 14 years against COVID-19.The DCGI has granted Covaxin an Emergency Use Listing (EUL) for the age group of 12 to 18 years on December 24, 2021.
ZycovD (Zydus Cadila vaccine) has been approved for emergency use in children over the age of 12.India began the most important phase of vaccination on January 3 with vaccines for adolescents in the age group of 15-18. On January 10, India rolled out precautionary doses to healthcare workers and those above 60 years of age with comorbidities. India made booster doses available to those above 18 from April 10.
